Caris Life Sciences Management
Management criteria checks 3/4
Caris Life Sciences' CEO is David Halbert, appointed in Jan 2008, has a tenure of 17.83 years. total yearly compensation is $2.25M, comprised of 33.3% salary and 66.7% bonuses, including company stock and options. directly owns 43.58% of the company’s shares, worth €3.20B. The average tenure of the management team and the board of directors is 7.8 years and 15.1 years respectively.
Key information
David Halbert
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 33.33% |
| CEO tenure | 17.8yrs |
| CEO ownership | 43.6% |
| Management average tenure | 7.8yrs |
| Board average tenure | 15.1yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$799m |
| Mar 31 2025 | n/a | n/a | -US$371m |
| Dec 31 2024 | US$2m | US$750k | -US$378m |
Compensation vs Market: David's total compensation ($USD2.25M) is about average for companies of similar size in the German market ($USD3.12M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
CEO
David Halbert (69 yo)
Dr. David Dean Halbert, M.D., DSc (h.c.) Founded Caris, Ltd. in 2005 and serves as its General Partner. Dr. Halbert serves as the Chairman, Founder and Chief Executive Officer at U.S.Caris MPI, Inc. (d/b/...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 17.8yrs | US$2.25m | 43.58% € 3.2b | |
| Executive Vice Chairman & Executive VP | 7.8yrs | US$1.20m | 0.19% € 13.8m | |
| President | 9yrs | US$1.21m | 0.063% € 4.6m | |
| Senior VP | 8.6yrs | no data | 0.000090% € 6.6k | |
| Senior VP & Chief Operations Officer | 2.8yrs | no data | no data | |
| Senior VP & CTO | no data | no data | no data | |
| Senior VP & Chief Scientific Officer | 2.8yrs | no data | no data | |
| Senior VP | no data | no data | no data | |
| Senior VP | 3.2yrs | no data | 0.010% € 763.8k | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Senior VP & Chief Commercial Officer | no data | no data | no data |
Experienced Management: 49J's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.1yrs | US$2.25m | 43.58% € 3.2b | |
| Executive Vice Chairman & Executive VP | 7.8yrs | US$1.20m | 0.19% € 13.8m | |
| Lead Independent Director | 17.8yrs | US$77.75k | 3.69% € 270.6m | |
| Director | 11.5yrs | US$50.00k | 0.036% € 2.6m | |
| Independent Director | 17.8yrs | US$63.00k | 0.11% € 8.2m | |
| Vice Chairman | 17.8yrs | US$162.50k | 0.19% € 13.8m | |
| Independent Vice Chairman | 16.2yrs | US$50.00k | 0.10% € 7.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.3yrs | US$74.00k | 0% € 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: 49J's board of directors are seasoned and experienced ( 15.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 12:17 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caris Life Sciences, Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |